Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Friday, November 6, 2026, inter-alia to considered and approved the following: 1. The Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. 2. Appointment of Mr. Mangesh Vaze as Senior Management Personnel. The ....

SUPRIYA LIFESCIENCE LTD . .J Creating true values tltat biud global he11lth November 6, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543434 NSE Symbol: SUPRIYA Dear Sir (s), Sub: Outcome of Board Meeting held on November 6, 2026 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Friday, November 6, 2026, inter-alia to considered and approved the following: 1. The Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026, are enclosed herewith, together with the Limited Review Report of the Statutory Auditors of the Company. 2. Appointment of Mr. Mangesh Vaze as Senior Management Personnel. Upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company approved the appointment of Mr. Mangesh Vaze as Chief Operating Officer and Senior Management Personnel of the Company effective from November 6, 2026. Information pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, read with relevant SEBI Circular(s) are enclosed herewith. The above information will also be available on the website of the Company. Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE SUPRIYA LIFESCIENCE LTD . .J Creating true values tltat biud global he11lth The Meeting of the Board of Directors of the Company commenced at 10:30 p.m. and concluded at 12.40 p.m. Kindly take the above information on your records. Thanking you, Yours faithfully, For Supriya Lifescience Limited Prachi Sathe Company Secretary & Compliance Officer Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE SUPRIYA LIFESCIENCE LTD . .J Creating true values tltat biud global he11lth Annexure A Details with respect to appointment of Senior Management Personnel under Regulation 30(6) read with Para A(7) of Part A of Schedule III of the Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024: Appointment of Mr. Mangesh Vaze as Chief Operating Officer and Senior Management Personnel of the Company: Sr. Details of events that need to be Information of such event(s) No provided 1. Reason for change viz. appointment, The Board of Directors of the Company has resignation, removal, death or otherwise today viz. November 6, 2026, approved the appointment of Mr. Mangesh Vaze, as Chief Operating Officer and Senior Management Personnel of the Company, with effect from November 6, 2026. 2. Date of appointment/cessation (as Date of Appointment: November 6, 2026 applicable) and term of appointment Term - Not Applicable 3. Brief Profile (in case of appointment) Mr. Vaze has completed B.E. Chemical Engineering and Executive MBA specialized in strategy, marketing, finance with approximately 34 years of professional experience in the areas of Production, Process Engineering, API Manufacturing and Operations. During his professional career, he has been associated with Zydus Lifescience Ltd., Cipla Ltd., Mylan Laboratories Ltd., Apotex Pharmachem India Pvt Ltd, Wockhardt Ltd., Orchid Chemicals & Pharmaceuticals Ltd. and Lupin Ltd. wherein he has handled responsibilities as in the fields as mentioned above. 4. Disclosure of relationships between directors Not Applicable. (in case of appointment of a director) Mr. Mangesh Vaze is not related to any Director of the Company. 5. Information as required pursuant to BSE Not Applicable. Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/ CML/2018/24, both dated 20 June 2018 Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE YOUR REF. KAKARIA AND ASSOCIATES LLP CHARTERED ACCOUNTANTS OUR REF. : UJWAL K. KAKARIA B.Com .. B.L.,F.C.A. SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A JAIPRAKASH H. SHETHIYA a.com., F.C.A. AMAR J. BHANUSHALI B.Com., D.T.M .. F.C.A. VINAYAKP. BAFANA B.Com., F.C.A, Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Con1pany Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,as amended. Board of Directors 0£ Supriya Lifescience Limited, 1. We have reviewed the accompanying statement of unaudited financial results of Supriya Lifescience Limited ("the Company") for the quarter ended 30th September 2026, ("the Statement''), being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations") 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 31, (lnd AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued then~undP.r and other accountine principleR eP.nerally accepted in Tndia and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3'. We conducted our reView of the Statement in accordance with the Sta,ndard on Review Engagements (SRE) 2410, "Review of Interim Financial 1nfomlation Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requites that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material .misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting _,,-::;;:.:;::=;:::::-,.__ 'b t.SSO?i:: s Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri • West ~'t, ~ bai. 400 053 Tel: 022 26744670. Email: mumbaj@kakaria.as1>oclj1tes.c0m, . ·:t M. NO. ~ Website: www.kakariaassociates.com · •. MUMBAI 1? ?,?fD ACC~'<S matters, and applying anal ti al d · . . y c an other review procedmes. A review is substantially less m scope than an audit conduct d · · d . A di . • . e m accor [Showing first 8,000 characters — download PDF for full document]